Access to the PPM Journal and newsletters is FREE for clinicians.

Non-Addictive New Opioid Could Help Deter Abuse

February 11, 2019
PPL-103 was shown to block dependency qualities in animal studies

A PPM Brief

A non-addictive opioid currently under development has demonstrated the potential to be a treatment for opioid, as well as cocaine, addictions, as published in a poster1 by Lawrence Toll, PhD, professor of biomedical science at the Charles E. Schmidt College of Medicine at Florida Atlantic University, and co-founder and chief neuropharmacologist of Phoenix PharmaLabs (Providence, UT). He presented the study results at a National Center for Advancing Translational Sciences-sponsored symposium on February 7th and 8th.

In the first-ever reported results of a study conducted by Toll et al, PPL-103, a compound under development by Phoenix PharmaLabs, demonstrated an ability to reduce cocaine self-administration among rats, particularly those who had dependency to cocaine, completely blocking reinstatement of cocaine-seeking among them. The drug could be a superior among its class with greatly reduced addiction liability and fewer side effects compared to traditional opioids, as well as its potential as a treatment for drug abuse.

PPL-103 was shown to block dependency qualities in mice. (Source: 123RF)

PPL-103 is a patented analog that binds strongly to all three opioid receptors in the brain (mu, kappa and delta), partially stimulating the receptors in a more balanced manner. This partial stimulation derives potent analgesic benefit from all three receptors, but is not strong enough to produce serious side effects associated with any single receptor, resulting in a first-ever opioid analgesic that appears to be non-addicting.

PPL-103 is currently being developed under preclinical studies and requirements for the filing of an Investigational New Drug (IND) and commencement of Phase I studies.

Last updated on: February 27, 2019
Continue Reading:
Federal Opioid Legislation Passed
close X